Current report
Open the filing on sec.gov
Calidi Biotherapeutics, Inc. (CLDI)
NYSE: CLDI · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
The companyfiscal 2022, as filed
Revenue$45,000
Net income-$25.4M
Earnings per share$2.99
Operating cash flow-$13.2M
Cash$590,000-73.6%
Debtn/a
Shareholders’ equity-$50.4M-59.6%
Shares, dilutedn/a
Return on equity-529.6%
The recordfrom its filings
Filings in 202641
Newest filingSep 25 · 8-K
Annual reportMar 27, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 monthsn/a
Insider buys, 12 monthsn/a
Patents granted6
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$17.5MCash from operations -$17.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.